Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

Esters, Nele; Vermeire, Séverine; Joossens, Sofie; Noman, Maja; Louis, Édouard; Bélaïche, Jacques; Vos, Martine De; Gossum, A. Van; Pescatore, Pierre; Fiasse, René; Pelckmans, Paul; Reynaert, Hendrik; Poulain, Daniel; Bossuyt, Xavier; Rutgeerts, Paul

doi:10.1111/j.1572-0241.2002.05689.x

Cited by 130 publications

(70 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ASCAs and P-ANCAs were not associated with response to antitumor necrosis factor-␣ therapy (61 ). A trend toward poor response to anti-tumor necrosis factor-␣ therapy in CD patients carrying the ANCA ϩ /ASCA Ϫ combination has been suggested (61 ). This was, however, not statistically significant and needs to be confirmed.…”

Section: Association With Clinical Phenotypesmentioning

confidence: 38%

“…Sanborn et al (60 ) reported that 90% of patients with refractory left-sided colitis were ANCA-positive vs 62% of patients with treatment-responsive UC (P ϭ 0.03). ASCAs and P-ANCAs were not associated with response to antitumor necrosis factor-␣ therapy (61 ). A trend toward poor response to anti-tumor necrosis factor-␣ therapy in CD patients carrying the ANCA ϩ /ASCA Ϫ combination has been suggested (61 ).…”

Section: Association With Clinical Phenotypesmentioning

confidence: 99%

See 1 more Smart Citation

Serologic Markers in Inflammatory Bowel Disease

Bossuyt¹

2006

Clinical Chemistry

184

136

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an enduring disease involving mostly young people, with symptoms of bloody diarrhea and abdominal cramps. Several antibodies have been associated with IBD, the 2 most comprehensively studied being autoantibodies to neutrophils (atypical perinuclear anti-neutrophil cytoplasmic antibodies) and anti-Saccharomyces cerevisiae antibodies. This review focuses on the value of these antibodies for diagnosing IBD, differentiating Crohn disease from ulcerative colitis, indeterminate colitis, monitoring disease, defining clinical phenotypes, predicting response to therapy, and as subclinical markers. Pancreatic antibodies and newly identified anti-microbial antibodies (anti-outer membrane porin C, anti-I2, and anti-flagellin) are also reviewed.

show abstract

Section: Association With Clinical Phenotypesmentioning

confidence: 38%

Section: Association With Clinical Phenotypesmentioning

confidence: 99%

Serologic Markers in Inflammatory Bowel Disease

Bossuyt¹

2006

Clinical Chemistry

184

136

View full text Add to dashboard Cite

show abstract

“…A study by Taylor et al ( 45 ) had demonstrated that patients with CD who had a positive p-ANCA were less likely to respond to therapy with infl iximab, and a subsequent result evaluating patients with negative ASCA and positive p-ANCA found a similar trend, although this did not reach statistical signifi cance ( 46 ). Several other studies have since demonstrated similar fi ndings, including a pediatric study ( 47 ).…”

Section: The Role Of Biomarkers Predicting Response To Treatmentsupporting

confidence: 45%

Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status

Lichtenstein¹,

McGovern²

2016

Am J Gastroenterol Suppl

View full text Add to dashboard Cite

Biomarkers, radiology fi ndings, and endoscopic studies, together with clinical assessment of patients with infl ammatory bowel disease, can be used to help determine prognosis, assess disease activity, and increasingly to inform treatment decision-making. This article reviews the current "state of the science" regarding the multitude of different tests that can be performed and how these can be used in the clinic to guide management. Initially, when patients present with symptoms suggestive of infl ammatory bowel disease (IBD), standard endoscopic studies and radiographic studies should be performed and the use of combinations of serologic and fecal markers may additionally be incorporated into patient assessment. Once the patient has a formal diagnosis, prognosis should be assessed and serologic evaluation may be used, but in conjunction with endoscopic and radiographic studies. Within the context of evaluating clinical predictors of disease (e.g., disease location, nutritional status, routine blood tests), early mucosal healing has been linked to better outcomes, and failure to heal the mucosa has been associated with poorer outcomes. Evaluation of response to therapy can be approximated with the use of biomarkers (e.g., C-reactive protein, fecal calprotectin, lactoferrin), and therapeutic drug monitoring has enabled us to assess levels of drug metabolites, drug levels, and antidrug antibodies to guide the ongoing management. Although there is not yet universal adoption of biomarkers to determine treatment choices (e.g., the use of anti-tumor necrosis factor therapy), biomarkers have enabled us to "fi ne tune" treatment of some patients with IBD. Establishing mechanisms of communicating these risks/benefi ts to patients will be a considerable challenge and remains a priority area of research.

show abstract

“…Furthermore, failure of anti-TNF therapy with infliximab has been linked to polymorphisms in the TNF/lymphotoxin-alpha region [27] and the pANCA + /ASCA-antibody profile [28]. It is likely the response to other new agents is affected, in many instances, by the genotype of the patient treated.…”

Section: Disease Heterogeneitymentioning

confidence: 99%

Evaluation of new therapies for inflammatory bowel disease

Carty¹,

Rampton²

2003

Brit J Clinical Pharma

View full text Add to dashboard Cite

The pathophysiology of inflammatory bowel disease (IBD) is gradually being unravelled and new therapies are being developed to target the disturbed biological processes. This article outlines the clinical features of IBD, its current therapy and pathogenesis. The difficulties for clinical pharmacologists and gastroenterologists associated with designing, executing and interpreting clinical trials in IBD are then discussed. The final section reviews methods that can used to demonstrate the pharmacological actions of new treatments in patients with IBD. It is emphasized that proof of the therapeutic efficacy of a novel agent with a specific mechanism of action yields not only clinical benefit to patients with IBD, but also indicates the importance of the targeted biochemical pathway in the pathogenesis of the disease.

show abstract

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

Abstract: In this cohort of infliximab-treated patients, neither ASCA nor pANCA could predict response to treatment. However, the combination pANCA+/ASCA- might warrant further investigation for its value in predicting nonresponse in patients with refractory luminal disease.

Cited by 130 publications

References 23 publications

Serologic Markers in Inflammatory Bowel Disease

Serologic Markers in Inflammatory Bowel Disease

Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status

Evaluation of new therapies for inflammatory bowel disease

Contact Info

Product

Resources

About